文献速递淋巴瘤

吉西他滨、顺铂、泼尼松、沙利度胺方案对比CHOP方案治疗初诊外周T细胞淋巴瘤的疗效与安全性及生物标志物分析

The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
PubMed 文献 · Br J Haematol · 2017-06-09

这项前瞻性随机对照开放标签临床试验于2010年7月至2016年6月纳入103例初诊外周T细胞淋巴瘤患者,随机分为GDPT组(52例)和CHOP组(51例)。GDPT组2年无进展生存率和总生存率均优于CHOP组,完全缓解率和总缓解率也更高,主要不良反应为血细胞减少,两臂急性毒性中等、可耐受且管理良好。

要点

  • GDPT组2年无进展生存率57% vs CHOP组35%(P=0.0035),2年总生存率71% vs 50%(P=0.0001)。
  • GDPT组完全缓解率52% vs CHOP组33%(P=0.044),总缓解率67% vs 49%(P=0.046)。
  • 血细胞减少是主要不良反应,两臂急性毒性中等、可耐受且管理良好。

核心结论

  • GDPT是初诊外周T细胞淋巴瘤有前景的潜在一线治疗新方案。

研究设计与样本

  • 前瞻性随机对照开放标签临床试验,2010年7月至2016年6月纳入103例初诊外周T细胞淋巴瘤患者,随机分为GDPT组52例和CHOP组51例。
  • 研究注册号为NCT01664975。

主要发现

  • GDPT组2年无进展生存率57% vs CHOP组35%(P=0.0035)。
  • GDPT组2年总生存率71% vs CHOP组50%(P=0.0001)。
  • GDPT组完全缓解率52% vs CHOP组33%(P=0.044)。
  • GDPT组总缓解率67% vs CHOP组49%(P=0.046)。
  • ERCC1、RRM1、TUBB3和TOP2A基因mRNA表达在患者间存在差异,但差异未达统计学显著,主要因样本量相对较小。

临床怎么用

  • 作者认为GDPT是初诊外周T细胞淋巴瘤有前景的潜在一线治疗新方案。
  • 这些生物标志物的确切特征仍有待明确。

局限性

  • ERCC1、RRM1、TUBB3和TOP2A基因mRNA表达差异未达统计学显著,主要因样本量相对较小。
  • 这些生物标志物的确切特征仍有待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We compared the efficacy and safety of gemcitabine, cisplatin, prednisone and thalidomide (GDPT) with standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) for patients with newly diagnosed peripheral T-cell lymphoma (PTCL) in a prospective randomized controlled and open-label clinical trial. Between July 2010 and June 2016, 103 patients were randomly allocated into two groups, of whom 52 were treated with GDPT therapy and 51 with CHOP therapy. The 2-year progression-free survival (PFS) and overall survival (OS) rates were better in the GDPT group than in the CHOP group (57% vs. 35% for 2-year PFS, P = 0·0035; 71% vs 50% for 2-year OS, P = 0·0001). The complete remission rate (CRR) and the overall response rate (ORR) in the GDPT group were higher than in the CHOP group (52% vs. 33%, P = 0·044 for CRR; 67% vs. 49%, P = 0·046 for ORR). Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms. mRNA expression of ERCC1, RRM1, TUBB3 and TOP2A genes varied among patients but the difference did not reach statistical significance, mainly due to the relatively small sample size. The precise characters of these biomarkers remain to be identified. In conclusion, GDPT is a promising new regimen as potential first-line therapy against PTCL. This study was registered at www.clinicaltrials.gov as #NCT01664975.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Li L, Duan W, Zhang L, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017. PMID: 28597542. doi:10.1111/bjh.14763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。